Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults.

Johanns TM, Ansstas G, Dahiya S.

J Natl Compr Canc Netw. 2018 Apr;16(4):451-454. doi: 10.6004/jnccn.2018.7029. No abstract available.

PMID:
29632063
2.

Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.

Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J.

Radiother Oncol. 2018 May;127(2):310-317. doi: 10.1016/j.radonc.2018.02.022. Epub 2018 Mar 11.

PMID:
29534829
3.

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH.

J Neurooncol. 2018 May;138(1):105-111. doi: 10.1007/s11060-018-2775-y. Epub 2018 Jan 27.

PMID:
29374809
4.

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.

Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G.

J Natl Compr Canc Netw. 2018 Jan;16(1):4-10. doi: 10.6004/jnccn.2017.7032.

PMID:
29295876
5.

Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base.

Huang J, Samson P, Perkins SM, Ansstas G, Chheda MG, DeWees TA, Tsien CI, Robinson CG, Campian JL.

J Neurooncol. 2017 Feb;131(3):593-601. doi: 10.1007/s11060-016-2331-6. Epub 2016 Nov 14.

PMID:
27844308
6.

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP.

Cancer Discov. 2016 Nov;6(11):1230-1236. Epub 2016 Sep 28.

7.

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series.

Ansstas G, Tran DD.

Case Rep Neurol. 2016 Jan 8;8(1):1-9. doi: 10.1159/000442196. eCollection 2016 Jan-Apr.

8.

Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia.

Ansstas G, Vij R.

Leuk Lymphoma. 2012 Jul;53(7):1273-81. doi: 10.3109/10428194.2011.653786. Epub 2012 Feb 13. Review.

PMID:
22220824
9.

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Rettig MP, Ansstas G, DiPersio JF.

Leukemia. 2012 Jan;26(1):34-53. doi: 10.1038/leu.2011.197. Epub 2011 Sep 2. Review.

10.

Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant.

Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C, Procknow E.

Leuk Lymphoma. 2010 Aug;51(8):1577-9. doi: 10.3109/10428194.2010.488709. No abstract available.

PMID:
20528249

Supplemental Content

Loading ...
Support Center